Revitalising its immuno-oncology portfolio, AstraZeneca (AZ) has expanded its 2015 research collaboration with Innate Pharma following promising Phase II data, in to a three-part deal that will see AZ hand over US$170 M in opt-in and upfront payments and commit up to US$5.2 B in option fees and milestone payments. In the first part, AZ will gain full oncology rights to monalizumab, exercising its option from the original agreement; the second grants AZ the options for IPH5201 and four preclinical assets; and lastly, the third part sees Innate gaining the US and EU rights for AZ’s recently approved Lumoxiti™ (moxetumomab pasudotox-tdfk), marking the latter’s entrance as a fully integrated biotech.